NexoBrid™ is well tolerated and associated adverse events are manageable
The safety profile of NexoBrid™ has been well characterised during the extensive multinational clinical trial programme. Overall the tolerability profile of NexoBrid™ is similar to that of SOC, mainly associated with the burn disease*. NexoBrid™ is not expected to have any specific deleterious effect. During the clinical development program of NexoBrid™, there was no indication of bleeding at the site of NexoBrid™ debridement. 7
For further information, please consult with the prescribing information.